Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Chemokine Stories

2012-05-29 09:02:10

Potential role in HIV treatment and prevention under study Scientists have identified a new HIV-suppressing protein in the blood of people infected with the virus. In laboratory studies, the protein, called CXCL4 or PF-4, binds to HIV such that it cannot attach to or enter a human cell. The research was led by Paolo Lusso, M.D., Ph.D., chief of the Section of Viral Pathogenesis in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part...

2012-04-12 02:38:32

MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 19th Annual Future Leaders in the Biotech Industry conference on Friday, April 20, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY. A live webcast of the presentation can be accessed through the Investors section of the Company's...

2012-04-03 09:22:40

A previously unknown serine protease forms part of the antibacterial defense arsenal of neutrophil granulocytes Neutrophil granulocytes comprise important defenses for the immune system. When pathogenic bacteria penetrate the body, they are the first on the scene to mobilize other immune cells via signal molecules, thereby containing the risk. To this end, they release serine proteases — enzymes that cut up other proteins to activate signal molecules. Scientists at the Max Planck...

2012-03-30 07:43:43

4 signaling substances control the transformation of T cells The thymus plays a key role in the body's immune response. It is here where the T lymphocytes or T cells, a major type of immune defense cells, mature. Different types of T cells, designated to perform specific tasks, arise from progenitor cells that migrate to the thymus from the bone marrow. Researchers at the Max Planck Institute of Immunology and Epigenetics in Freiburg have generated artificial thymus tissue in a mouse...

2012-02-13 12:31:00

MOUNTAIN VIEW, Calif., Feb. 13, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the completion of its initial public offering of 4,500,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock. All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share. J.P. Morgan and Citigroup acted as...

2012-02-08 08:14:00

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the pricing of its initial public offering of 4,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by ChemoCentryx. In addition, the underwriters have a 30-day option to purchase up to an additional 675,000 shares of common stock from ChemoCentryx to cover over-allotments, if any. Shares of...

2012-01-20 07:00:00

SAN DIEGO, Jan. 20, 2012 /PRNewswire/ -- Carolus Therapeutics, Inc. today announced the publication of preclinical data showing that CT-2009 disrupts heteromers formed by the platelet-derived chemokines CCL5 (RANTES) and CXCL4, thereby preventing lung damage in multiple mouse models of acute lung injury (ALI). The study, published online on the website of the American Journal of Respiratory and Critical Care Medicine (AJRCCM), showed that CCL5-CXCL4 chemokine heteromers are...

2012-01-09 06:29:41

(Ivanhoe Newswire) — Give it time, time heals all wounds, these words of wisdom are true when it comes to healing. As healing progresses, the need to grow new blood vessels is critical to providing nutrients and oxygen; however, it takes time to grow these necessary blood vessels. Wound healing requires complex interactions between cells resident at the damaged site and infiltrating immune cells. Endothelial progenitor cells (EPCs) are cells that come from the bone marrow and are...

2012-01-05 14:07:00

MOUNTAIN VIEW, Calif., Jan. 5, 2012 /PRNewswire/ -- ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA). ChemoCentryx recently reported positive...

2012-01-03 14:05:15

Wound healing requires complex interactions between cells resident at the damaged site and infiltrating immune cells. As healing progresses, the growth of new blood vessels is critical to provide nutrients and oxygen. Endothelial progenitor cells (EPCs) are cells that come from the bone marrow and are key to the production of new vessels, but the signals that direct their emigration from the bone marrow are unknown. In this paper, Toshikazu Kondo and colleagues at Wakayama Medical University,...